Palatin Technologies announced that its collaboration partner, AstraZeneca, has decided to discontinue their pharma partnering agreement for the development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.
AstraZeneca remains committed to this pharma partnering collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.
AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist, was a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Obesity Partnering
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity